Tom 7, Nr 1 (2022)
Artykuł przeglądowy
Opublikowany online: 2022-02-10
Wyświetlenia strony
5021
Wyświetlenia/pobrania artykułu
215
Off-label use of medicinal products in oncology: exercising due diligence or experimental activity?
1
, 2
, 2
Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2022;7(1):27-33.
Streszczenie
One of the primary responsibilities of a physician is to diagnose and treat diseases with due diligence. Exercising due diligence in treatment process involves, among others, the use of optimal diagnostic, therapeutic and follow-up management in accordance with the current state of medical knowledge. Each medicinal product has the Summary of Product Characteristics which defines, among others, registered indications, the age group for which the product is registered, the dosing scheme, and route of administration of the product. Polish law does not refer directly to the admissibility of products that use off-label nor does it include regulations forbidding such activities. Considering a number of problems associated with products which use off-label and, on the other hand, commonness of such activities, it is necessary to introduce legal regulations defining the legitimacy and admissibility of such methods of proceeding.
Słowa kluczowe: off-label useoncology treatmentmedical experimentdue diligencereimbursement of drugs
Referencje
- The Act on the Profession of Doctor and Dentist of 5.12.1996., ie. DzU 2021 r., pos. 719.
- The Pharmaceutical Law of 06.09.2001, ie. DzU 2021 r., pos. 974, with changes.
- Dal Pan GJ. Monitoring the safety of off label medicine use. WHO Drug Information 2009: 21–22.
- Stafford RS. Regulating off-label drug use--rethinking the role of the FDA. N Engl J Med. 2008; 358(14): 1427–1429.
- Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. OJ L 311/67. https://eur-lex.europa.eu/legal-content/PL/TXT/PDF/?uri=CELEX:32001L0083&from=EN (01.08.2021).
- https://rejestrymedyczne.ezdrowie.gov.pl/rpl/search/public (01.08.2021).
- Matusewicz W. Stosowanie leków w onkologii i hematologii w zakresie wskazań do stosowania lub dawkowania, lub sposobu podawania odmiennych niż określone w Charakterystyce Produktu Leczniczego, Warszawa 2012. http://www.korektorzdrowia.pl/wp-content/uploads/prezes-aotm-wojciech-matusewicz-stosowanie-lekow.pdf (01.08.2021).
- Saiyed MM, Ong PS, Chew L. Off-label drug use in oncology: a systematic review of literature. J Clin Pharm Ther. 2017; 42(3): 251–258.
- Herbrand AK, Schmitt AM, Briel M, et al. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs. JAMA Netw Open. 2021; 4(3): e210380.
- Bun S, Yonemori K, Sunadoi H, et al. Safety and Evidence of Off-Label Use of Approved Drugs at the National Cancer Center Hospital in Japan. JCO Oncol Pract. 2021; 17(3): e416–e425.
- Poole SG, Dooley MJ. Off-label prescribing in oncology. Support Care Cancer. 2004; 12(5): 302–305.
- Rückeshäuser P. Off label use: the legal problems of drug application beyond the licensed use. , Hamburg 2011: 1–386.
- Emmerich J, Dumarcet N, Lorence A. France's new framework for regulating off-label drug use. N Engl J Med. 2012; 367(14): 1279–1281.
- Choonara I, Conroy S. Unlicensed and off-label drug use in children: implications for safety. Drug Saf. 2002; 25(1): 1–5.
- Masełbas W, Członkowski A. Stosowanie produktów leczniczych poza wskazaniami rejestracyjnymi. Przewodnik Lekarza. 2008; 3: 81–87.
- Vrancken I. Off-label Prescription of Medication. European Journal of Health Law. 2015; 22(2): 165–186.
- Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Archives of Internal Medicine. 2006; 9: 1021–1026.
- Kapko M. In: Zielińska E. ed. Ustawa o zawodach lekarza i lekarza dentysty. Comment. Wolters Kluwer Polska 2008: 528.
- The Judgment of the Court of Appeal in Warsaw of 14.02.2014, no, VI ACa 1000/13, LEX nr 1469448.
- The Judgment of the Supreme Court of 24.11.2011, no, I CSK 69/11, OSNC 2012/5/63 2012.
- The Resolution of the Supreme Court of 26.10.2011, no, III CZP 58/11, OSNC 2012/5, pos. 59.
- Widłak T. nterpretacja klauzuli ,,aktualna wiedza medyczna” w polskim prawie — zarys zagadnień epistemologicznych i metodologicznych. Gdańskie Studia Prawnicze. 2017; 38.
- Luty O. Zaniechanie zlecenia produktu leczniczego poza zarejestrowanym wskazaniem a odpowiedzialność cywilna lekarza. PiM. 2014; 2: 132–150.
- American Society of Clinical Oncology. Reimbursement for cancer treatment: coverage of off-label drug indications. J Clin Oncol. 2006; 24(19): 3206–3208.
- Lim M, Shulman DS, Roberts H, et al. Off-label prescribing of targeted anticancer therapy at a large pediatric cancer center. Cancer Med. 2020; 9(18): 6658–6666.
- The Announcement of the Minister of Health of 21.06.2021, on the list of reimbursed medicines, foods for special medical purposes and medical devices as of 1st July 2021. https://www.gov.pl/web/zdrowie/obwieszczenia-ministra-zdrowia-lista-lekow-refundowanych.
- Chromiec Z, Hoffmann E. Stosowanie leków poza wskazaniami — przesłanki oraz refundacja. Folia Cardiologica. 2020; 15(2): 188–191.
- Zajdel. Dopuszczalność stosowania produktów leczniczych poza ChPL w programie lekowym „Leczenie przetoczeniami immunoglobulin w chorobach neurologicznych”. Neuroedu.pl. file:///C:/Users/User/Downloads/neuroedu%202016%20Dopuszczalno%C5%9B%C4%87%20stosowania.pdf (01.08.2021).
- Safjan M. Prawo i medycyna. Ochrona praw jednostki a dylematy współczesnej medycyny. , Warszawa 1998: 172.
- Kondrat M. (ed.). Prawo farmaceutyczne. Komentarz, ed. II. WKP 2016.
- The Regulation of the Minister of Finance, Development Funds and Regional Policy on mandatory liability insurance of the entity conducting medical experiment, DzU 2020, pos. 2412.
- Kubiak R. Nowe uwarunkowania prawne przeprowadzania eksperymentów medycznych. PS. 2021; 1: 5–26.
- The Judgment of the Court of Appeal in Kraków of 12.10.2007, no., I ACa 920/07, LEX no 570272.
- Kwinta P. Stosowanie leków poza rejestracją u dzieci – perspektywa lekarza. Przegląd Lekarski. 2011; 68: 1–3.
- Aagaard L, Kristensen K. Off-label and Unlicensed Prescribing in Europe: Implications for Patients’ Informed Consent and Liability. International Journal of Clinical Pharmacy. 2018; 40(3): 509–512.
- Gęsicka DK. Odpowiedzialność za szkody wyrządzone przez produkty lecznicze – zagadnienia wybrane. Prawo i Medycyna. 2013(3-4): 189–208.
- The Judgment of the Supreme Court of 18.01.2013, no, IV CSK 431/12, Lex no 1275006.
- Zajdel J. Prawo medyczne. PZWL, Warszawa 2019.
- The Judgment of the Court of Appeal in Warsaw of 9.04.2019, no, akt V ACa 147/18, Lex no 2668829.
- The Judgment of the Court of Appeal in Warsaw of 19.02.2019, no, V ACa 119/18, Lex no 2631471.
- The Civil Code of 23.04.1964, ie. DzU 2020, pos. 1740.
- Kubiak R. Prawo medyczne. C.H.Beck, Warszawa 2017: 291–295.
- The Judgment of the Supreme Court of 28.08.1972, no akt II CR 296/72, OSNC, No 5/1973, pos. 86.
- The Judgment of the Court of Appeal in Kraków of 06.09.2012 r., no akt I ACa 723/12, LEX no 1236722.
- The Judgment of the Supreme Court of 28.09.1999 r., no akt II CKN 511/96, LEX no 453701).
- The Judgment of the Court of Appeal in Szczecin of 11.05.2017, no akt I Aca 560/15, LEX no 2376937.
- The Judgement of the Court of Appeal in Katowice of 18.01.2017 r., no akt V ACa 146/16, LEX no 2233014.
